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Abstract 
Background: Alterations in cellular metabolism are considered as hallmarks of cancers, however, to recognize these 
alterations and understand their mechanisms appropriate techniques are required. Our hypothesis was to determine 
whether dominant bioenergetic mechanism may be estimated by comparing the substrate utilisation with different 
methods to detect the labelled carbon incorporation and their application in tumour cells.
Methods: To define the bioenergetic pathways different metabolic tests were applied: (a) measuring CO2 production 
from [1-14C]-glucose and [1-14C]-acetate; (b) studying the effect of glucose and acetate on adenylate energy charge; 
(c) analysing glycolytic and TCA cycle metabolites and the number of incorporated 13C atoms after [U-13C]-glucose/
[2-13C]-acetate labelling. Based on [1-14C]-substrate oxidation two selected cell lines out of seven were analysed 
in details, in which the highest difference was detected at their substrate utilization. To elucidate the relevance of 
metabolic characterisation the expression of certain regulatory factors, bioenergetic enzymes, mammalian target of 
rapamycin (mTOR) complexes (C1/C2) and related targets as important elements at the crossroad of cellular signalling 
network were also investigated.
Results: Both [U-13C]-glucose and [1-14C]-substrate labelling indicated high glycolytic capacity of tumour cells. How-
ever, the ratio of certain 13C-labelled metabolites showed detailed metabolic differences in the two selected cell lines 
in further characterisation. The detected differences of GAPDH, β-F1-ATP-ase expression and adenylate energy charge 
in HT-1080 and ZR-75.1 tumour cells also confirmed the altered metabolism. Moreover, the highly limited labelling of 
citrate by [2-13C]-acetate—representing a novel functional test in malignant cells—confirmed the defect of TCA cycle 
of HT-1080 in contrast to ZR-75.1 cells. Noteworthy, the impaired TCA cycle in HT-1080 cells were associated with high 
mTORC1 activity, negligible protein level and activity of mTORC2, high expression of interleukin-1β, interleukin-6 and 
heme oxygenase-1 which may contribute to the compensatory mechanism of TCA deficiency.
Conclusions: The applied methods of energy substrate utilisation and other measurements represent simple assay 
system using 13C-acetate and glucose to recognize dominant bioenergetic pathways in tumour cells. These may offer 
a possibility to characterise metabolic subtypes of human tumours and provide guidelines to find biomarkers for 
prediction and development of new metabolism related targets in personalized therapy.
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Background
Following the discovery by Otto Warburg high glucose 
uptake and lactate production—even in the presence of 
oxygen—have been documented in nearly all tumours 
[1, 2]. The glycolytic phenotype was interpreted as a 
response to damaged cellular respiration to satisfy the 
ATP demand of the tumours [3, 4]. However, recently 
numerous studies have showed that ATP production in 
tumours could be related to both glycolysis and mito-
chondrion despite of the defected oxidative phosphoryla-
tion [4–6]. These intriguing findings received support by 
demonstrating multiple auxiliary processes for ATP syn-
thesis [6–8].
However, the relative contribution of glycolysis and 
TCA cycle in ATP production is rather variable in dif-
ferent tumours during progression [4, 5] because the 
metabolic profile of the tumours depends on both the 
changes in malignant cells and on the microenvironment 
[9]. The survival of tumour cells in unfavourable condi-
tions may be attributed to the reprogramming of the 
metabolism, as a crucial hallmark of the malignant cells 
[8]. Thus changes of tumour metabolism require indi-
vidual and regular monitoring. To define the dominant 
bioenergetic pathway as bioenergetic signature based on 
the ratio of metabolic markers of glycolysis and mito-
chondrial respiration has been reported previously [10]. 
In the present study the bioenergetic signature was esti-
mated by comparing the utilization of glucose and ace-
tate in multiple assays. As acetate is mainly metabolized 
in TCA cycle contrary to glucose acetate labels only TCA 
cycle. [11, 12]. Therefore, the comparison of acetate and 
glucose utilization can be useful to decide the dominant 
bioenergetic process. Since metabolic reprogramming is 
directed through regulatory factors it has been suggested 
that the relevant regulatory mechanisms should also be 
taken into account [13]. Hence the used complex multi-
ple assay system includes measurements and analysis on 
substrate utilization and certain related enzymes as the 
following: (a) measurements on CO2 production derived 
from [1-14C]-glucose and [1-14C]-acetate; (b) estimation 
of adenylate energy charge in the presence and absence 
of glucose and acetate [14]; (c) analyse the expression of 
metabolic enzymes (G6PDH, GAPDH, β-F1-ATPase); (d) 
use of stable isotope-mass spectrometric technique to 
compare glycolysis and TCA cycle activity after labelling 
tumour cells with [U-13C]-glucose or [2-13C]-acetate; (e) 
test the TCA cycle function by measuring the number of 
13C-carbons in citrate, derived from [2-13C]-acetate;.
To gain an insight into the regulation of the aberrant 
bioenergetic phenotype the expression of mTOR com-
plex 1 and 2 (mammalian target of rapamycin) and of 
their activity related proteins [15, 16], heme-oxigenase-1 
(HO-1) [17] and the proinflammatory interleukins (IL-
1β), IL-6, IL-8)) [18, 19] were examined in tumour cell 
cultures. In contrast to the traditional 14C-substrate 
labelling method, applying the combination of complex 
assays and measurements help to map the correlations 
and allow to get more information about the highly dif-
ferent metabolic and regulatory characteristics of cell 
lines—as it was observed in the two selected cell lines in 
which the highest difference was detected at their sub-
strate utilization.
Methods
All materials were purchased from Sigma-Aldrich, except 
where indicated in the text. HT-1080 (human fibrosar-
coma) and ZR-75.1 (human mammary adenocarcinoma) 
cell lines were selected for detailed characterisation 
from other human cells (MDA-MB231, BT747—breast 
and HepG2—hepatocellular carcinoma; Oscort—osteo-
sarcoma, U937—histiocytic lymphoma, isolated fibro-
blasts) based on their different energy substrate oxidizing 
capacities.
To obtain subconfluent cultures 5  ×  105 HT-1080 
and 106 ZR-75.1 cells were seeded in 10  ml RPMI1640 
medium with 10 % fetal bovine serum (FBS), 100 IU peni-
cillin and 50  µg/ml streptomycin. In metabolic experi-
ments the medium was replaced by energy substrate-free 
D5030 medium. All experiments were performed with 
previously established in  vitro cell lines which are not 
requiring special ethical approvals, The Institutional Tis-
sue- and Cell Culture Laboratory has official permission.
Measurement of energy‑substrate oxidation
Cultures were incubated at 37  °C placed in an air-flow 
chamber and perfused with CO2 free air. Cells were 
labelled with 0.2  µCi/ml [1-14C]-glucose (specific activ-
ity 55  mCi/mmol) or [1-14C]-acetate (specific activity 
57  mCi/mmol (Institute of Isotope-Zrt. Budapest) for 
1 h. The CO2 released by the cells was trapped on solid 
alkaline adsorbent, attached to the air-flow chamber and 
its radioactivity measured with Geiger–Müller counter.
Expression of mRNA
Total RNAs were isolated with Trizol (Invitrogen). 
Reverse transcription and real time PCR were performed 
following the instructions of the manufacturer (M-MLV 
Reverse Transcriptase kit—Invitrogen; ABI power SYBR® 
Green PCR Master mix and ABI Prism 7000 Sequence 
Detection System—Applied Biosystems). PCR primers are 
summarized in Supplementary Table (ST1). Results were 
obtained as threshold cycle (CT) values. Expression levels 
were calculated by using the 2−ΔCT method and β-actin 
for normalization as reported previously.
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Expression analysis of mTOR complex related proteins, 
certain metabolic enzymes and inflammatory cytokines 
at protein level
Proteins extracted from cells were quantitated using 
Quant-iT protein assay (Invitrogen), separated by SDS-
PAGE. Proteins transferred to PVDF membrane were 
incubated with the following reagents: anti-phospho-
mTOR (Ser2448), anti-phospho-S6 (Ser 235/236), anti-
Rictor (Cell Signaling Technologies) and anti-β-actin 
(Sigma-Aldrich), anti-GLUT1 (Abcam), anti-β-F1-
ATPase (anti-ATPB Abcam), anti-GAPDH (Serotec), 
anti-pan-Akt (Cell Signaling Technologies), anti-phos-
pho-(Ser473)-Akt 1 (Abcam) finally with biotinylated 
secondary antibodies, avidin-HRP complex (Vectastain 
Elite ABC Kit, Vector) and enhanced chemiluminescence 
technique (Pierce ECL Western Blotting Substrate).
The concentrations of extra- and intracellular cytokines 
were determined by cytokine bead assay (CBA immu-
noassay) were measured by flow cytometry. The assay 
was carried out using the CBA Human Soluble Protein 
Master Buffer Kit (BD Biosciences, San Jose, CA, USA; 
558264) and CBA Human IL-8 (558277), IL-6 (558276) 
and IL-1β (558279) Flex Sets (BD Biosciences) accord-
ing to the manufacturer’s instructions. The samples were 
acquired on FACSCalibur (BD Biosciences) and analysed 
by FCAP Array software (BD Biosciences).
Stable isotope‑mass spectroscopic detection 
of metabolites
Cells incubated in D5030 medium for one hour were 
labelled with 10 mM [U- 13C]-glucose or [2-13C]-acetate 
(Cambridge Isotope Laboratories, Andover, MA, USA). 
The key metabolites of the glycolytic and TCA cycle 
pathways were extracted and analysed by applying liquid 
chromatography–mass spectrometry (LC–MS) based on 
the protocol described previously [20, 21].
Determination of adenylate energy charge
To evaluate the distinct contributions of glucose and ace-
tate on the level of adenylate energy charge (AEC) ATP, 
ADP and AMP were determined in starving cell cultures. 
To this end the RPMI1640 medium was replaced by the 
energy substrate deprived medium (D5030) and the cul-
tures were divided into three groups as follows: (a) sup-
plemented with 10  mM glucose, (b) supplemented with 
10 mM acetate, (c) kept in starving conditions. Adenylate 
nucleotides were extracted from the cells with methanol-
acetic acid (9:1) were separated by isocratic elution using 
Aquasil C18 column principally as reported previously 
[22] and analysed by applying LKB PE NELSON 3000 
interface (Perkin-Elmer Corporation).
Statistical analysis
The experiments were performed in triplicate with 3–5 
parallel samples and the data evaluation was performed 
using Student’s t test (two-tailed); p  <  0.05 was consid-
ered statistically significant.
Results
Comparing glucose and acetate oxidation
Comparative measurements of released 14CO2 derived 
from [1-14C]-glucose and [1-14C]-acetate showed cer-
tain noteworthy differences among the investigated 
tumour cells. The rate of [1-14C]-glucose oxidation was 
rather similar in the investigated tumour cells, except in 
HT-1080 cells. On the contrary the release of 14CO2 from 
[1-14C]-acetate showed great variance especially between 
the ZR-75.1 and HT-1080 tumour cells (Table 1). The bio-
energetic signature calculated from these data indicated 
that HT-1080,—in contrary to ZR-75.1 cells—preferen-
tially oxidize glucose and have modest capacity to oxidize 
acetate. Hence this opposite preference for energy sub-
strate has offered promising model to study bioenergetic 
mechanism in these tumour cells.
Expression of enzymes related to bioenergetic pathways
To clarify the background of this some key enzymes 
related to energy metabolism were studied in HT-1080 
and ZR-75.1. The protein expression of GLUT-1 (glu-
cose transporter) showed high level in both cell lines. 
However, the differences between HT-1080 and 
ZR-75.1 in glucose/acetate utilization were supported 
when mRNA expression of enzymes such as glucose-
6-phosphate-dehydrogenase (G6PDH), glycolytic 
Table 1 Oxidation of  [1-14C]-glucose and  [1-14C]-acetate 
in human tumour cells measured by the release of 14CO2
Tumour cells incubated nutrient-free medium were labelled for 1 h with 0.2 µCi/
ml [1-14 C]-glucose or [1-14C]-acetate and the released 14CO2 measured. Data 
from three independent measurements and 3 parallel samples
Cell culture 14CO2 in the cell culture count per 250 s/10
6 cells
[1‑14C]‑glucose (A) [1‑14C]‑Na‑acetate (B) A/B
HT-1080 11334 ± 2202 377 ± 33 30.1
Fibroblast 3973 ± 684 924 ± 243 4.3
MDA-MB231 3360 ± 584 1344 ± 104 2.5
HepG2 3255 ± 1145 2305 ± 378 1.4
BT747 3081 ± 247 2924 ± 227 1.1
Oscort 5336 ± 171 5580 ± 1240 1.0
ZR-75.1 3450 ± 966 8947 ± 1915 0.4
U937 5948 ± 191 15149 ± 3221 0.4
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
and mitochondrial β-F1-ATPase were studied. Higher 
G6PDH (~20  % higher expression) and significantly 
higher mRNA expression of GAPDH in HT-1080 than 
ZR-75.1 cells were detected by real time PCR. At the 
same time mRNA expression of the β-F1 subunit of 
the ATP-synthase complex was significantly higher in 
ZR-75.1. The significant mRNA expression differences 
were confirmed at GAPDH and β-F1-ATPase protein 
levels by Western blot analysis, as well. In fact this bio-
energetic signature, the GAPDH/β-F1-ATPase ratio, is in 
harmony with substrate oxidation results and confirms 
the more extensive glycolytic phenotype in the HT-1080 
than in the ZR-75.1 cells (Fig. 1).
13C‑glucose labelled glycolytic and TCA cycle metabolites
Applying [U-13C]-glucose labelling and LC–MS the high-
est incorporation of 13C atom among the investigated 
metabolites was measured in lactate both in HT-1080 
and in ZR-75.1, noteworthy, that higher level was found 
in the former cell line. At the same time there was sig-
nificant difference in the labelling of TCA cycle inter-
mediates between the two cell lines. In HT-1080 cells 
[U-13C]-glucose preferentially donated 13C atoms to 
lactate, G6P and R5P whereas in ZR-75.1 tumour cells 
malate surpassed the labelling of lactate (Table 2). Thus 
glucose more extensively fuels TCA cycle in ZR-75.1 
than in HT-1080 tumour cells. To study and confirm the 
importance of the detected distinctions we analysed the 
metabolic profile of U937 tumour cells, which showed—
similarly to ZR-75.1—a relative low glucose oxidizing 
ability (Table  1). 1-14C labelling in glucose/acetate 0.4). 
The incorporation of 13C-carbon from U-13C-glucose 
showed similarity to ZR-75.1 cells. The ratio of labelled 
metabolites (13C-malate/lactate) in U937 was as low 
as in ZR-75.1 and significantly lower than in HT-1080 
(13C-malate/lactate ratio- ZR-75.1: 0.87 and U937: 1.17, 
however, HT-1080: 13.74). Hence the difference in the 
activity of glycolysis and mitochondrial respiration may 
be expressed quantitatively by dividing labelled lactate 
and malate as bioenergetic signature.
Testing the function of TCA cycle
As it has been reported that in the mitochondria the 
second carbon of acetyl-CoA remains in the TCA cycle 
through several cycling therefore labelling with [2-13C]-
acetate results increasing number of 13C-atoms in citrate. 
Consequently the enrichment of 13C-atoms in citrate 
represents the intact function of TCA cycle. Applying 
[2-13C]-acetate labelling and analysing the ratio of the 
unlabelled and labelled, especially the multiple labelled 
citrate in our samples could indicate the activity of TCA 
cycle and allow to investigate the cellular TCA capacity 
deeply and showed the metabolic differences between the 
two cell lines. In the present study citrates with multiple 
13C atoms (1–6 number of 13C atoms) suggest intact TCA 
cycle in ZR-75.1, whereas the low number (maximum 
two) of 13C atoms in citrate indicates impaired TCA 
cycle in HT-1080 tumour cells (Fig.  2). We measured 
the capacity of TCA cycle in U937 to find correlation in 
surpassed 13C labelling into citrate to ZR-75.1 based on 
their previously found similarities (Table 1; “13C-glucose 
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Fig. 1 Different expression of certain enzymes related to bioenergetic mechanism at mRNA and protein levels. a G6P-DH, GAPDH, β-F1-ATP-ase 
(beta1-ATP-ase) mRNA expression differences in HT-1080 and ZR-75.1 cells measured by real time PCR (the results as relative expression to β-actin 
was calculated from threshold cycle values (ΔCT method) of two independent isolation with 3-3 parallels, *- significant). b GLUT1, GAPDH, β-F1-ATP-
ase (beta1-ATP-ase), β-actin protein expression detected by Western blot in HT-1080 and ZR-75.1 cells
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labelled glycolytic and TCA cycle metabolites” section). 
The results - the intensively incorporated 13C into citrate 
(1-5 number of 13C atoms)—could also confirm the meta-
bolic similarities between ZR-75.1 and U937 (unlabelled 
citrate 11  %; labelled 1C—19  %, 2C—24  %, 3C—24  %, 
4C—19 %, 5C—3 %).
Effect of glucose and acetate on adenylate energy charge 
(AEC)
Demonstrating the intact and impaired TCA cycle in 
ZR-75.1 and HT-1080 tumour cells respectively we 
focused our interest on the energy level of these cells in 
the absence and presence of glucose or acetate. The AEC 
values of HT-1080 and ZR-75.1 cells were rather similar 
in nutrient rich medium (0.75–0.85) but decreased in the 
absence of energy substrates (i.e. in D5030 medium), in 
fact more extensively in HT-1080 cells. However, supply-
ing glucose but not acetate to the starving HT-1080 cells 
elevation of the AEC value could be achieved. On the 
contrary in ZR-75.1 cells both acetate and glucose were 
similarly effective in the restoration of the AEC value. 
Thus this experimental setting provided further data 
for more efficient utilization of glucose over acetate by 
HT-1080 cells (Table 3).
Putative modulators of the aberrant bioenergetic 
pathways
As it has been presumed that reprogramming of bioener-
getic mechanisms is controlled by cellular regulation we 
compared some points of this regulatory network—the 
expression and/or activity of Akt/mTOR signalling ele-
ments, HO-1 and proinflammatory cytokines in HT-1080 
and ZR-75.1 tumour cells with the above described dif-
ferent metabolic profiles, TCA cycle activity.
HT-1080 cells showed higher mRNA expression of 
IL-1β and IL-6 by real time PCR. We could confirm these 
differences at protein level by cytokine bead assay using 
flow cytometry. IL-1β and IL-6 proteins were undetect-
able in ZR-75.1 cells and in their supernatant, as well. 
According to our PCR results, high intracellular level 
of IL-1β (159.2 ±  13.2  ng/106 cells) and lower intracel-
lular (81.8  ±  9.5  pg/106 cells) but high extracellular 
(6.456  ±  0.78  ng/106 cells) level of IL-6 protein were 
measured in HT-1080. IL-8 —other proinflammatory 
cytokine—expression was also studied at both mRNA 
and protein level but such a difference was not detected 
(IL-8 protein level—7.5  ±  1.3  ng/106 HT-1080 cells; 
9.48  ±  1.52  ng/106 ZR-75.1 cells). Moreover, we could 
detect other interesting differences between these two 
Table 2 Concentration of glycolytic and TCA cycle metabolites in tumour cells labelled with [U-13C]-glucose
Tumour cell line: ZR-75.1, HT-1080 Culture medium: D5030
Labelling: [U-13 C]-glucose 10 mM for 1 h. Data from three independent measurements and 3 parallel samples
Metabolites ZR‑75.1 HT‑1080
ng/106cells
13C 12C 13C 12C
G6P/F6P 26.3 ± 2.3 10.1 ± 1.3 72.0 ± 7.1 7.4 ± 1.3
Lactate 39.26 ± 1.6 35.9 ± 6.8 61.2 ± 36.0 70.2 ± 12.6
Citrate 14.9 ± 1.7 33.9 ± 4.8 23.2 ± 4.3 33.9 ± 4.5
Succinate 17.1 ± 7.9 11.8 ± 2.3 ND ND
Malate – 28.6 ± 5.9 – 30.2 ± 1.0
[1-13C]:7.9 ± 2.5 – [1-13C]: ND –
[2-13C]: 22.2 ± 7.0 – [2-13C]: 4.7 ± 0.4 –
[3-13C]: 23.5 ± 7.2 – [3-13C]: 1.9 ± 0.7 –
[4-13C]: 13.1 ± 2.5 – [4-13C]: ND –
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Fig. 2 Differences in the number of 13C atoms of citrate in ZR-75.1 
and HT-1080 tumour cells after 13C acetate labelling (% data were 
calculated from three independent measurements and 3 parallel 
samples)
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cells in HO-1 expression level, HT-1080 cells showed 
higher (more than 15×) mRNA expression than ZR-75.1 
cells.
The further interest focused on mTOR as an impor-
tant central signalling integrator in regulation of protein 
synthesis and bioenergetic mechanism. The two mTOR 
complexes (C1 and C2) represent distinct regulatory 
signals. In this respect it is noteworthy that different 
metabolic profiles of the two investigated cells could be 
associated to distinct expression patterns of mTOR com-
plexes. As Fig.  3 shows HT-1080 cells expressed prefer-
entially mTORC1 activity (represented by high p-mTOR 
and p-S6—with relative no/low Rictor expression). At 
the same time in the ZR-75.1 cells showed high p-mTOR 
with lower p-S6 and higher Rictor level as a sign of 
potential high mTORC2 expression and activity. Related 
to mTOR complexes the amount of Akt protein detected 
by pan–Akt antibody was similar in both cell lines, but 
higher level of phosphorylated Ser473 form correlates to 
the higher mTORC2 complex activity and functioning 
TCA cycle of the ZR-75.1 cells (Fig. 3).
Discussion
The accumulated evidences on the glycolytic phenotype 
and repressed mitochondrial function as contributors 
of tumour progression have initiated attempts to intro-
duce simple but relevant assays to characterise the bio-
energetic profile of human tumour samples [23–25]. The 
majority of studies in this area involves measurements of 
labelled intermediates in the bioenergetic pathways using 
radioactive or stabile isotope substrates [21, 25, 26] and 
different detecting instruments, which represent a great 
challenge.
Glucose and glutamine are considered the basic and 
indispensable nutrients subsequently they are the most 
widely used energetic substrates in metabolic analysis of 
tumour cells. It has been assumed that using two sub-
strates would provide more information about the rela-
tive capacity of glycolysis and TCA cycle than either one 
alone. As the catabolic product of fatty acid oxidation 
acetate is channelled toward TCA cycle it appeared to 
be an ideal complementary energetic substrate beside 
glucose [27, 28]. Thus acetate can fuel exclusively mito-
chondrial respiration therefore it is a promising way to 
detect the bioenergetic mechanism. Some recently pub-
lished new studies from clinical samples using NMR 
illustrated that especially acetate could be energy sub-
strate of glioblastomas and brain metastases [29]. In our 
study we compared acetate and glucose labelling in the 
substrate oxidation and in the intracellular metabolite 
concentration analysis by LC–MS. Our results show 
Table 3 Elevation of adenylate energy charge (AEC) by glucose and acetate in starving tumour cell cultures
AEC =
ATP+1/ 2ADP
ATP+ADP+AMP
Data from three independent measurements and 3 parallel samples
* p < 0.05
Adenylate energy charge (AEC*) value
ZR‑75.1 mammary adenocarcinoma (A) HT‑1080 fibrosarcoma (B)
D5030 medium 0.54 ± 0.15 (100 %) 0.38 ± 0.10 (100 %)
D5030 medium + glucose 0.61 ± 0.15 (113 %) 0.64 ± 0.18 (168 %)*
D5030 medium + acetate 0.69 ± 0.094 (128 %)* 0.46 ± 0.16 (121 %)
p-S6 (32 kDa)
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Fig. 3 Different expression of mTOR activity related proteins and Akt 
in HT-1080 and ZR-75.1 cells. phospho-mTOR (p-mTOR—the active 
mTOR kinase), phospho-S6 (p-S6—mTORC1 activity related phospho-
protein), Rictor (mTORC2 specific protein), Akt and anti-phospho-
(Ser473)-Akt expression in HT-1080 and ZR-75.1 cells detected by 
Western blot. The higher amount of p-S6 with low Rictor expression 
in HT-1080 suggest that mTORC1 activity is high in HT-1080 and lower 
in ZR-75.1 cells. mTOR activity could be released mainly in mTORC2 
complex in ZR-75.1 cells (low level of p-S6 and high level of Rictor 
and phospho-(Ser473)-Akt)
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that using two substrates such as glucose and acetate 
has more advantage to get detailed information about 
the relative capacity of glycolysis and TCA cycle. More-
over, our novel evaluation from LC–MS analysis after 
13C-acetate labelling is capable for highlighting the 
impairment of TCA cycle in tumour cells. To under-
line the importance of this metabolic profile analysis we 
demonstrated some points of the potential regulatory 
background in the two studied cells, which correlate 
well to the alterations in bioenergetic phenotype of the 
cells.
The radioactive technology has still an important role 
in metabolic investigations including released 14CO2 
measuring, detecting the oxidation of energy substrates 
offer a simple and cost-effective assay to estimate the 
dominant bioenergetic mechanism. Applying LC–MS 
technique with [U-13C]-glucose and [2-13C]-acetate to 
investigate tumour specific bioenergetic profile, we dem-
onstrated that the highest level of the incorporated 13C 
atoms derived from [13C]-glucose into lactate both in 
HT-1080 and in ZR-75.1 tumour cells correlates to the 
other results related to high glucose oxidation and AEC 
measurement. The LC–MS technique allowed to raise the 
question whether an identical metabolic phenotype may 
also be recognized by measuring the unlabelled metabo-
lites which could be interesting in future metabolic analy-
sis of tumour samples. This may have special interest. We 
found that the unlabelled lactate also reflects to the dif-
ferences in the glycolytic activity of the two investigated 
tumours in vitro. However, it should be considered that 
for example lactate production in tumour cells in vivo is 
not exclusively derived from actual glycolytic flux (e.g. 
uptake from microenvironment). The low number of 13C 
atoms in malate and citrate after labelling with [U-13C]-
glucose or [2-13C]-acetate respectively may suggest that 
TCA cycle is less effective (as we detected in HT-1080 
in contrast to ZR-75.1 cells). This provides example for 
detectable relative dominance of the bioenergetic path-
ways in tumour cells. The remarkably high unlabelled 
malate concentration may suggest the function of the 
anaplerotic route to replenish TCA cycle.
Elevated lactate and reduced concentration of TCA 
cycle metabolites were described in certain human 
tumour samples and in patients’ body fluids [30–32] by 
metabolomics mainly with GC or LC–MS, NMR, but 
other analytical methods have been developing further. 
However, there is still no consensual advice in using the 
analytical techniques to measure metabolic profile of 
tumour samples (certainly these assays are expensive, 
time-consuming and need large sample size). In our 
assays we did not measured the complete metabolite-
profile, we only measured and evaluated selected metab-
olites (G6P, R5P, lactate, citrate, malate, succinate). In 
that way we could rationalize our sources, we could save 
time, instrumental capacity and we optimised the sensi-
tivity and apply this methods for smaller sample size. The 
latter was performed after not only glucose but acetate 
labelling, as well—the metabolism of malignant cells have 
not been investigated previously in that way in compari-
son of acetate and glucose consumption. Upon studying 
the distribution of 13C-carbon, derived from [13C-U]-
glucose, between glycolytic and TCA cycle intermediates 
high lactate and low malate labelling indicated glyco-
lytic phenotype and impaired TCA cycle in the HT-1080 
tumour cells, but not in the ZR-75.1 cells. Moreover, the 
highly limited labelling of citrate by [2-13C]-acetate—rep-
resenting a novel functional test—confirmed the above 
detected defect in TCA cycle of HT-1080 tumour cells. 
Consequently glucose and acetate differently elevate the 
reduced level of adenylate energy charge depending on 
the dominant bioenergetic mechanism.
An other suggestion comparing the expression of glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) and 
β-F1-ATPase an inverse relationship could be concluded 
between glycolysis and mitochondrial respiration in vari-
ous human tumour tissues. In fact it was proposed that 
β-F1-ATPase could be used for monitoring progression 
of breast cancer [10, 31]. We could confirm this and we 
can also suggest GAPDH/β-F1-ATPase expression stud-
ies in tumour tissue samples by immunohistochemistry 
based on our Western blot results and its harmony with 
the metabolic characterisation data.
Evaluating our results from different measurements 
in HT-1080 and ZR-75.1 cells we could summarise that 
assays–measuring: (a) 14CO2 from glucose/14CO2 from 
acetate ratio; (b) AEC at the presence of glucose/AEC 
at the presence of acetate ratio; (c) lactate/malate from 
13C-glucose labelling; d. the number of incorporated 
13C into citrate from 13C-acetate and e. the GAPDH/β-
F1-ATPase expression (summarized in Table  4)—could 
indicate the metabolic differences at distinct level. From 
these assays, especially from analysis of the selected 
metabolites (G6P, R5P, lactate, citrate, malate, succinate) 
by LC–MS after 13C-glucose and acetate labelling we 
could conclude the condition of mitochondrial function 
and TCA cycle capacity (impaired TCA or potentially 
functioning one in HT-1080 or ZR-75.1 respectively) 
beside the admitted high glycolytic activity.
Our experimental results allowed to find some correla-
tions of certain regulatory factors and the effected bioen-
ergetic pathways or invasive growth in HT-1080 contrary 
to ZR-75.1 (harbouring less metastatic potential) tumour 
cells [33]. This expectation was met when high expression 
of proinflammatory interleukins and HO-1 were detected 
in the TCA cycle impaired and metastatic HT-1080 cells 
compared with the non-metastatic ZR-75.1 cells. It was 
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reported that IL-1β and IL-6 stimulate glucose metabo-
lism and promote tumour progression [16]. The high 
expression of HO-1 in HT-1080 cells deserves special 
attention as recent studies documented the stimulation 
of invasive growth and metastatic behaviour associated 
with high expression of HO-1 in lung cancers (NSCLCs) 
[17, 34].
At present we may speculate on the possibility that 
activated rescue mechanism related to HO-1 in TCA 
cycle impaired HT-1080 tumour cells may enable mito-
chondrial ATP synthesis through a potential alternative 
HO-1 dependent way as previously reported in fuma-
rate hydratase 1 deleted kidney cells especially in kidney 
tumour cells [6].
To study mTOR signalling—which has well docu-
mented role in the regulation of metabolic and sur-
vival functions—we compared the expression of related 
phospho-proteins and Rictor in HT-1080 and ZR-75.1 
cells [35]. It is well known that malignant transforma-
tion is often accompanied by deregulated mTOR activity 
(mainly higher mTOR activity status) which helps to syn-
thesise and activate the elements/proteins of the cellular 
apparatus of altered phenotype [36]. The high mTOR 
activity is providing the enzymatic background for gly-
colysis, pentose-phosphate pathway and glutaminoly-
sis, moreover the HIF1α production [35, 36]. Present 
study contributed fascinating data to the distinct func-
tion of two mTOR complexes in terms of bioenergetic 
regulation. The high glycolytic activity with impaired 
TCA cycle in HT-1080 cells was accompanied by domi-
nant mTORC1 activity, which is in harmony with the 
reported mTORC1 activity related promotion of gly-
colysis and the detected GLUT-1 and HIF1α expres-
sion. These correlate to the previously described HIF1α 
expression in HT-1080 and ZR-75.1 at normal condi-
tion which could be induced further in hypoxia [37, 38]. 
On the other hand mTORC2 is rather closely related to 
oxidative phosphorylation as it is localized in the endo-
plasmic reticulum sub-compartment which is bound to 
mitochondria [39, 40]. In this respect it is noteworthy, 
that expression of mTORC2 complex related Rictor pro-
tein was dominant and the related high amount of p-Akt 
was also detected in ZR-75.1 tumour cells bearing intact 
TCA cycle. However, the glycolytic capacity and the 
related GLUT-1 expression, glucose consumption are 
also not negligible in ZR-75.1 cells.
Conclusion
In summary, the present study demonstrated the fea-
sibility of novel and cost-effective assays to define the 
bioenergetic signature based on the comparison of the 
cellular utilisation of acetate and glucose and to study 
further specific elements in the regulation of the ener-
getic homeostasis of the cells. The feasibility of this 
complex energetic profiling assay system (applying mini-
mum two labelling substrates—13C glucose and acetate 
in the measurements of selected metabolites and their 
ratio and evaluating the number of incorporated 13C 
atoms into certain metabolites—for example into citrate) 
could define the bioenergetic signature of tumour cells. 
Moreover, the applied experimental setting provided fur-
ther evidence for the relationship between the altered 
phenotype and the impaired/functioning TCA cycle 
in HT-1080/ZR-75.1 cells. Furthermore the presented 
complex test system correlated well with the found regu-
latory differences at protein level—such as mTOR com-
plexes, G6PDH, GAPDH, GLUT-1, β-F1-ATP-ase, HO-1, 
IL-1ß, IL-6—, and with substrate oxidation/AEC results 
(Table 4). Based on our observations the presented assays 
may offer a possibility to characterise metabolic subtypes 
of human tumours and provide guidelines to find bio-
markers for prediction and development of new metabo-
lism related targets in personalized therapy.
Abbreviations
AEC: adenylate energy charge; CT: threshold cycle; ECL: enhanced chemilumi-
nescence; G6PDH: glucose-6-phosphate dehydrogenase; GAPDH: glyceral-
dehyde-3-phosphate dehydrogenase; LC–MS: liquid chormatography–mass 
spectrometry; HO: heme oxygenase; HRP: horseradish peroxydase; mTOR: 
mammalian target of rapamycin; mTORC: mTOR complex; p-mTOR: phospho-
mTOR; pS6: phospho-S6; TCA: trycarboxylic acid.
Table 4 Bioenergetic signature based on the utilization of glucose and acetate in various assays
Summarised data calculated from the results of different assays
a The ratio was calculated from molar values
b mRNA expression level normalized to β-actin
Characteristic data of glycolysis and TCA capacity with different assays ZR‑75.1 HT‑1080
14CO2 from glucose/from acetate 0.4 30.1
AEC at the presence of glucose/at the presence of acetate 0.88 1.39
Labelled13C-lactate/13C-malate from13C-glucosea 0.87 13.74
Number of incorporated13C atoms into citrate from13C-acetate 1–6 1–2
GAPDH/ß-F1-ATPaseb 1.27 9.81
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